Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.66 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.53 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | GPX4 | P36969 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 3/20 | 0.50 |
| ▸ | CCND1 | P24385 | 3/20 | 0.50 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30023116 | 1.00 | PARP1 (0.66) | PARP1TRPV1FAAHGPX4CDK4 | |
| SCHEMBL8359246 | 0.84 | PARP1 (0.68) | PARP1TRPV1GPX4 | |
| SCHEMBL969392 | 0.84 | TRPV1 (0.72) | TRPV1FAAHGPX4CDK4CCND1 | |
| SCHEMBL8360520 | 0.84 | PARP1 (0.71) | PARP1TRPV1FAAHGPX4CDK4 | |
| SCHEMBL8360521 | 0.83 | PARP1 (0.73) | PARP1TRPV1GPX4 | |
| SCHEMBL8360509 | 0.82 | PARP1 (0.69) | PARP1TRPV1GPX4 | |
| SCHEMBL8360524 | 0.82 | PARP1 (0.58) | PARP1TRPV1FAAHGPX4CDK4 | |
| SCHEMBL2270578 | 0.81 | PARP1 (0.57) | PARP1TRPV1FAAHGPX4CDK4 | |
| SCHEMBL8363099 | 0.81 | PARP1 (0.67) | PARP1TRPV1FAAHGPX4CDK4 | |
| SCHEMBL8360518 | 0.80 | PARP1 (0.56) | PARP1TRPV1FAAHGPX4CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | claimed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | claimed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | claimed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | PARP1 931/4885TRPV1 853/4885FAAH 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.